Search Results

HOW FBC’S HEALTH INFORMATION LINE SUPPORTS YOU: Q&A WITH HEALTH INFORMATION OFFICER SHARI SHAW

Vision health information can be hard to navigate. Whether you or someone you know has been newly diagnosed with an eye disease, or have been living with an eye disease and are...

RESEARCH NEWS

June 2025 Gene Therapy for XLRP does not meet primary endpoint in Phase 3 trial The Phase 3 LUMEOS trial studying the gene therapy botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa (XLRP)...

IMPROVING AMD TREATMENTS BY STUDYING CELL MOVEMENT

Age-related macular degeneration (AMD) is the leading cause of vision loss in people over the age of 50, affecting approximately 1.4 million Canadians. There are two kinds of AMD: dry AMD which...

BIOLOGICAL MECHANISMS DRIVING HDAC INHIBITOR TREATMENT EFFECTS IN RP

Valproic acid (VA), belongs to a family of drugs called HDAC inhibitors (HDACi) and has been tested as a potential treatment for retinitis pigmentosa (RP) with mixed results. In some clinical trials,...

NEW VISION TREATMENT MAY STOP PHOTORECEPTOR CELLS FROM DYING

FBC-funded researcher, Dr. Philippe Monnier identifies new treatment to stop photoreceptor cells from dying. Research published in March 2020 in The Journal of Clinical Investigation has identified a new target that may...

INFORMATION ABOUT COVID-19 AND YOUR EYE HEALTH

We understand this time of uncertainty may be confusing. We have prepared answers to some questions you may have about your eye health during these times. Different levels of government and professional...